Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2006-10-31
2006-10-31
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S086000, C544S243000, C544S244000
Reexamination Certificate
active
07129227
ABSTRACT:
A method of treating viral infections, and in particular HIV-1, hepatitis B virus, and herpesviruses, is disclosed. The method comprises administering to a subject in need of such treatment an infection-combating amount of a phospholipid or phospholipid derivative.
REFERENCES:
patent: 2086585 (1937-07-01), Taub et al.
patent: 2087132 (1937-07-01), Taub et al.
patent: 2108765 (1938-02-01), Domagk
patent: 2209383 (1940-07-01), Bock
patent: 2439969 (1948-04-01), Fourneau
patent: 2445393 (1948-07-01), Fourneau
patent: 2513747 (1950-07-01), Sallman et al.
patent: 2606909 (1952-08-01), Blicke
patent: 2689790 (1954-09-01), Mowry et al.
patent: 2950253 (1960-08-01), Kling et al.
patent: 3054678 (1962-09-01), Michener et al.
patent: 3694473 (1972-09-01), Eibl et al.
patent: 4093714 (1978-06-01), Tolman et al.
patent: 4096278 (1978-06-01), Queuille
patent: 4119714 (1978-10-01), Kny et al.
patent: 4159988 (1979-07-01), Eibl et al.
patent: 4221732 (1980-09-01), Oette et al.
patent: 4235877 (1980-11-01), Fullerton
patent: 4291024 (1981-09-01), Turcotte
patent: 4329302 (1982-05-01), Hanahan et al.
patent: 4426525 (1984-01-01), Hozumi et al.
patent: 4444766 (1984-04-01), Bosies et al.
patent: 4471113 (1984-09-01), MacCoss
patent: 4540521 (1985-09-01), Garst et al.
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4619917 (1986-10-01), Lee et al.
patent: 4622392 (1986-11-01), Hong et al.
patent: 4661509 (1987-04-01), Gordon et al.
patent: 4724232 (1988-02-01), Rideout et al.
patent: 4797479 (1989-01-01), Shuto et al.
patent: 4816450 (1989-03-01), Bell et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4826823 (1989-05-01), Cook et al.
patent: 4835263 (1989-05-01), Nguyen et al.
patent: 4837023 (1989-06-01), Eibl
patent: 4841039 (1989-06-01), Chu et al.
patent: 4880782 (1989-11-01), Eckstein et al.
patent: 4921951 (1990-05-01), Shuto et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 4997761 (1991-03-01), Jett-Tilton
patent: 5026687 (1991-06-01), Yarchoan et al.
patent: 5034394 (1991-07-01), Daluge
patent: 5138045 (1992-08-01), Cook et al.
patent: 5221696 (1993-06-01), Ke et al.
patent: 6030960 (2000-02-01), Morris-Natschke et al.
patent: 3726945 (1989-10-01), None
patent: 3934820 (1991-04-01), None
patent: 4010228 (1991-10-01), None
patent: 0094586 (1983-11-01), None
patent: 0109255 (1984-05-01), None
patent: 0146258 (1985-05-01), None
patent: 0142333 (1985-06-01), None
patent: 0145303 (1985-06-01), None
patent: 0252310 (1987-06-01), None
patent: 0335396 (1989-02-01), None
patent: 0310109 (1989-04-01), None
patent: 0 350 287 (1990-01-01), None
patent: 0348859 (1990-01-01), None
patent: 0416401 (1990-08-01), None
patent: 0434450 (1990-12-01), None
patent: 0506704 (1991-07-01), None
patent: 0632048 (1994-06-01), None
patent: 1561630 (1969-03-01), None
patent: 2 239 243 (1991-06-01), None
patent: 42-13841 (1967-08-01), None
patent: 49-100224 (1974-09-01), None
patent: 61-238793 (1986-10-01), None
patent: 1029319 (1989-01-01), None
patent: 10-293129 (1989-11-01), None
patent: 90/00555 (1990-01-01), None
patent: 90/15601 (1990-12-01), None
patent: 90/05736 (1991-03-01), None
patent: 91/05558 (1991-05-01), None
patent: 91/09602 (1991-07-01), None
patent: 91/18914 (1991-12-01), None
patent: 91/19726 (1991-12-01), None
patent: 92/03462 (1992-03-01), None
patent: 92/06192 (1992-04-01), None
patent: 93/00910 (1993-01-01), None
patent: 93/08807 (1993-05-01), None
patent: 93/16091 (1993-08-01), None
patent: 93/16092 (1993-08-01), None
patent: 93/17020 (1993-09-01), None
patent: 93/21191 (1993-10-01), None
Hirsch et al., Antiviral Agents, Fields Virology, Third Edition, Lippincott—Raven Publishers, p. 431, 1996.
Aggarwal, “Synthesis and Biological Evaluation of Prodrugs of Zidovudine”,J. Med. Chem., 33, 1505-10 (1990).
Boldanova, et al., “Protective effect of Phosphatidylcholine-containing Liposomes in Experimental Toxic Hepatitis”,Vopr. Med. Khim, 32, No. 3 (1986) Chemical Abstracts, 105, p. 67, Abstract No. 35587k (1986).
Bosies, et al., “Chemical Abstracts”, 115CA;72142p 1991.
Chen, “Design and Synthesis of Novel Nucleoside Analogs as Potential Antiviral Agents”,Abstract American Assoc. of Pharmaceutical Scientists, Orlando Fl., (1993).
Crumpton, “Novel Lipid Analogs with Cytostatic and Cytocidal Activity”,Submitted to Anticancer Res., vol. 8, No. 6, pp. 1361-1366 (Nov.-Dec. 1988).
Daniel, “Alkyl-Linked Diglygerides Inhibit Protein Kincase C Activation by Diacylglycerols”,Biochemical&Biophysical Res. Comm., 151, 291-97 (Feb. 29, 1988).
Dietzfelbinger, “Cytotoxic and Purging Effects of ET-18-OCH3 in Human Malignant Lymphoid Cell Lines in Vitro”,Abstract 2472, Proceedings of the American Assoc. for Cancer Res., 31, 416 (Mar. 1990).
Fields, “Human Immunodeficiency Virus Induces Phosphorylation of its Cell Surface Receptor”,Nature, 333, 278-80 (May 19, 1988).
Harada, “Infection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay”,Science, 229, 563-566 (Aug. 9, 1985).
Himmelmann, “Studies on the Cross Resistance Pattern of Membrane-Toxic Lipids in Vitro”,Abstract 2448, Proceedings of the American Assoc. for Cancer Res., 31, 416 (Mar. 1990).
Hsu, L., et al., “Synthesis of Anti-Restricted Pyramidine Acyclic Nucleosides”,Journal of Organic Chemistry, vol. 57, No. 12, pp. 3354-3358, (1992).
Kasnar, B., et al., “Synthesis of 2′,3′-Dideoxy- and 3′-Azido-2′,3′-Dideoxy-Pyridazine Nucleosides as Potential Antiviral Agents”,Nucleosides&Nucleotides, 13(1-3), pp. 459-479, (1994).
Korba, “Use of a Standardized Cell Culture Assay to Assess Activities of Nucleoside Analogs Against Hepatitus B Virus Replication”,Antiviral Res., 19, 55-70 (1992).
Krugner-higby, L., et al., “Membrane-Interactive Phosphilipids Inhibit HIV Type 1-Induced Cell Fusion and Surface gp160/gp120 Binding to Monoclonal Antibody”,AIDS Research and Human Retroviruses, 11, 705-712, (1995).
Krugner-higby, et al., “Novel Membrane Interactive Ether Lipid Analogs Inhibits HIV-1 Glycoprotein Interaction with CD4+ Cells”,Abstract from 32nd Interscience Conf on Antimicrobial Agents and Chemotherapy, Anaheim, 164, (Oct. 11-14, 1992).
Kucera, L.S., et al., “Activity of Triciribine and Triciribine-5′-Monophosphate Against Human Immunodeficiency Virus Types 1 and 2”,Aids Research and Human Retroviruses, vol. 9, No. 4, pp. 307-314, (1993).
Kucera, “Effect of Membrane-Active Ether Lipid (EL) Analogues on Human Immunodefiency Virus Production Meausured by Plaque Assay”,Annuals of the New York Acad. of Sciences, 546-548 (Dec. 26, 1990).
Kucera, “Inhibition of HIV-1 Plaque Formation by a Novel Class of Membrane-Active Ether Lipid Analogs”,International Conference on AIDS, Abstract No. W.C.O.21, Jun. 4-9, 1989, p. 528.
Kucera, “Inhibition of Human Immunodeficiency Virus-1 (HIV-1) by Novel Membrane Interactive Ether Lipids”,Abstract No. 2470, Proceedings of the American Assoc. for Cancer Res., 31, 416 (Mar. 1990).
Kucera, L., et al., “Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-Medicated Cell Fusion by Synthetic Phospholipid Analogs”,Antiviral Research(1995).
Kucera, “Investigations on Membrane Active Ether Lipid Analogs that Alter Functional Expression of HIV-1 Induces Glycoproteins and Inhibit Pathogenis”,Abstract, Innovations in Theraphy of Human Viral Diseases, Symposium, Research Triangle Park,16, (Dec. 6-9, 1992).
Kucera, L., et al., “Novel Ether Lipid Analogs of Platelet Activating Factor with Anti-Hepatitis B Virus Activity”,Abstract, ICAAC Orlando,(1994).
Kucera, “Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation”,AIDS Research and Human Retroviruses,6, 491-501 (1990)
Ishaq Khalid S.
Kucera Louis S.
Morris-Natschke Susan L.
Coleman Brenda
Morgan & Lewis & Bockius, LLP
University of North Carolina at Chapel Hill
Wake Forest University
LandOfFree
Lipid analogs for treating viral infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipid analogs for treating viral infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipid analogs for treating viral infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3714765